X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (232) 232
Publication (51) 51
Conference Proceeding (27) 27
Book Review (16) 16
Magazine Article (10) 10
Patent (6) 6
Newspaper Article (4) 4
Book / eBook (3) 3
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (130) 130
humans (113) 113
oncology (112) 112
melanoma (62) 62
female (60) 60
middle aged (52) 52
cancer (51) 51
male (50) 50
article (43) 43
melanoma - pathology (38) 38
aged (37) 37
adult (35) 35
prognosis (32) 32
melanoma - drug therapy (30) 30
ipilimumab (29) 29
immunotherapy (28) 28
metastasis (28) 28
tumors (28) 28
cell line, tumor (24) 24
aged, 80 and over (23) 23
tissue array analysis (22) 22
melanoma - genetics (21) 21
skin neoplasms - pathology (21) 21
survival (20) 20
melanoma - metabolism (19) 19
apoptosis (18) 18
care and treatment (18) 18
proteins (18) 18
research (18) 18
antineoplastic agents - therapeutic use (17) 17
immunohistochemistry (17) 17
neoplasm metastasis (17) 17
expression (16) 16
malignant-melanoma (16) 16
mutation (16) 16
skin neoplasms - drug therapy (16) 16
brain neoplasms - secondary (15) 15
cells (15) 15
medicine, research & experimental (15) 15
melanoma - secondary (15) 15
abridged index medicus (14) 14
analysis (14) 14
animals (14) 14
carcinoma, renal cell - pathology (14) 14
cell biology (14) 14
neoplasm staging (14) 14
tissue microarrays (14) 14
treatment outcome (14) 14
chemotherapy (13) 13
dermatology (13) 13
health aspects (13) 13
metastatic melanoma (13) 13
antibodies, monoclonal - therapeutic use (12) 12
cohort studies (12) 12
immunology (12) 12
kidney neoplasms - pathology (12) 12
nivolumab (12) 12
therapy (12) 12
biomarkers (11) 11
clinical trials (11) 11
melanoma - mortality (11) 11
mice (11) 11
neoplasms (11) 11
pathology (11) 11
survival rate (11) 11
brain metastases (10) 10
breast neoplasms - pathology (10) 10
disease-free survival (10) 10
gene expression regulation, neoplastic (10) 10
genetic aspects (10) 10
medicine (10) 10
pembrolizumab (10) 10
renal cell carcinoma (10) 10
skin cancer (10) 10
young adult (10) 10
biomarkers, tumor - metabolism (9) 9
blockade (9) 9
blotting, western (9) 9
diagnosis (9) 9
drug therapy (9) 9
kinases (9) 9
melanoma - therapy (9) 9
open-label (9) 9
programmed cell death 1 receptor - antagonists & inhibitors (9) 9
protein (9) 9
research article (9) 9
skin neoplasms - metabolism (9) 9
antibodies, monoclonal - adverse effects (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
cancer therapies (8) 8
carcinoma, renal cell (8) 8
cutaneous melanoma (8) 8
disease progression (8) 8
gene expression (8) 8
kaplan-meier estimate (8) 8
multivariate analysis (8) 8
patients (8) 8
proto-oncogene proteins b-raf - genetics (8) 8
risk factors (8) 8
safety (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 976 - 983
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 122 - 133
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2016, Volume 113, Issue 8, pp. 2170 - 2175
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2542 - 2552
Journal Article
Nature Genetics, ISSN 1061-4036, 09/2012, Volume 44, Issue 9, pp. 1006 - 1014
Journal Article
Nature Genetics, ISSN 1061-4036, 08/2015, Volume 47, Issue 9, pp. 996 - 1002
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2012, Volume 7, Issue 2, pp. e31331 - e31331
Introduction: We assessed expression of p85 and p110 alpha PI3K subunits in non-small cell lung cancer (NSCLC) specimens and the association with mTOR... 
ONCOGENIC K-RAS | MAMMALIAN TARGET | GROWTH-FACTOR RECEPTOR | APOPTOSIS | BRONCHIAL EPITHELIAL-CELLS | P85 REGULATORY SUBUNIT | AKT/PROTEIN-KINASE-B | NEGATIVE REGULATION | MULTIDISCIPLINARY SCIENCES | DUAL PI3K/MTOR INHIBITOR | PHOSPHOINOSITIDE 3-KINASE | Lung Neoplasms - drug therapy | Class Ia Phosphatidylinositol 3-Kinase - metabolism | Adenocarcinoma - pathology | TOR Serine-Threonine Kinases - metabolism | Tissue Array Analysis | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Lung Neoplasms - pathology | Male | Immunoenzyme Techniques | TOR Serine-Threonine Kinases - antagonists & inhibitors | Adenocarcinoma - metabolism | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - metabolism | Adenocarcinoma - drug therapy | Blotting, Western | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Drug Synergism | Carcinoma, Squamous Cell - drug therapy | Signal Transduction - drug effects | Fluorescent Antibody Technique | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Squamous cell carcinoma | Oncology, Experimental | Lung cancer, Small cell | Phospholipids | Research | Lung cancer, Non-small cell | Cancer | TOR protein | Biotechnology | Biomedical research | Lung cancer | Clinical trials | AKT protein | Kinases | Medical diagnosis | Autophagy | Proteins | Cell growth | Inhibition | Quantitative analysis | Medical research | Epidermal growth factor receptors | Melanoma | Non-small cell lung carcinoma | Rapamycin | Survival | 1-Phosphatidylinositol 3-kinase | Medicine | Chemotherapy | Inhibitors | Protein synthesis | Cell lines | Mutation | Apoptosis | Tumors | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4270 - 4279
Purpose: With recent approval of inhibitors of PD-1 in melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma, extensive efforts are under way... 
UNTREATED MELANOMA | METASTATIC MELANOMA | LUNG-CANCER | PEMBROLIZUMAB | ONCOLOGY | ADVANCED MELANOMA | ANTIBODY | NIVOLUMAB | BLOCKADE | RENAL-CELL CARCINOMA | IPILIMUMAB | Tissue Array Analysis | Humans | Middle Aged | Carcinoma, Renal Cell - genetics | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - administration & dosage | Carcinoma, Renal Cell - immunology | Melanoma - genetics | Aged, 80 and over | Adult | Female | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma, Renal Cell - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Renal Cell - pathology | Melanoma - pathology | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Melanoma - drug therapy | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Biomarkers, Tumor - immunology | Programmed Cell Death 1 Receptor - genetics | Biotechnology | Cell survival | PD-1 protein | Tumor cells | Lung cancer | Melanoma | Antibodies | Inflammation | Patients | Studies | CTLA-4 protein | Inhibitors | Immune checkpoint | Experimental design | PD-L1 protein | Cell lines | Biomarkers | Bioindicators | Immunofluorescence | Clear cell-type renal cell carcinoma | Tumors | Cancer | Index Medicus | lung cancer | PD-L1 | melanoma | renal cell carcinoma | PD-1 inhibitors
Journal Article